Treatment of Advanced Hepatocellular Carcinoma
common.study.values.description
“Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma”
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


Drug - H3B-6527
H3B-6527 by mouth once or twice daily at specified doses.
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
common.study.values.clinical-trial-id
NCT02834780
participant.views.study.view.id
QeZgQa